Rybrevant Faspro

Active Ingredient(s): Amivantamab + Hyaluronidase-lpuj
FDA Approved: * February 13, 2026
Pharm Company: * JANSSEN BIOTECH
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Rybrevant Faspro Subcutaneous Injection
NDC: 57894-510
Labeler:
Janssen Biotech, Inc.
Rybrevant Faspro Subcutaneous Injection
NDC: 57894-514
Labeler:
Janssen Biotech, Inc.
Rybrevant Faspro Subcutaneous Injection
NDC: 57894-515
Labeler:
Janssen Biotech, Inc.
Rybrevant Faspro Subcutaneous Injection
NDC: 57894-522
Labeler:
Janssen Biotech, Inc.